Tirzepatide Dosage Chart
Tirzepatide Dosage calculations for a 60 mg vial use the same once-weekly escalation amounts evaluated in human research and listed in the current product information. Adding 3 mL in this lyophilized-vial calculation produces 20 mg/mL, so each U-100 unit contains 200 mcg.
- Reconstitute: Add 3 mL of the documented sterile diluent to produce 20 mg/mL.
- Research frequency: Once weekly by subcutaneous administration in the cited human trials.[1][2][4]
- Weekly research range: The cited programs evaluated target amounts through 15 mg weekly after stepwise escalation.[1][2][3][4]
- Easy measuring: 1 U-100 unit = 0.01 mL = 200 mcg.
- Vial size: The 60 mg label is total nominal vial content, not a weekly amount.
- Vial coverage: At the 2.5 mg starting stage, one vial supplies 24 full weekly amounts. At the 15 mg research stage, one vial supplies 4 full weekly amounts. These are mass calculations, not vial storage or discard periods.
Research context: For mechanisms, human research, outcomes, limitations, and safety context, read the Tirzepatide Peptide research overview.
Dosing & Reconstitution Guide
The same published weekly escalation schedule converted for a 60 mg vial
Standard Weekly Escalation Schedule (3 mL = 20 mg/mL)
| Study Phase | Weekly Amount | U-100 Units | Volume |
|---|---|---|---|
| Weeks 1 to 4 | 2.5 mg | 12.5 units | 0.125 mL |
| Weeks 5 to 8 | 5 mg | 25 units | 0.25 mL |
| Weeks 9 to 12 | 7.5 mg | 37.5 units | 0.375 mL |
| Weeks 13 to 16 | 10 mg | 50 units | 0.5 mL |
| Weeks 17 to 20 | 12.5 mg | 62.5 units | 0.625 mL |
| Weeks 21+ | 15 mg | 75 units | 0.75 mL |
Frequency: Once weekly by subcutaneous administration. The current product label starts at 2.5 mg for four weeks, then increases to 5 mg. When additional escalation is selected, increases occur in 2.5 mg steps after at least four weeks at the current amount. The studied maintenance targets were 5 mg, 10 mg, and 15 mg.[1][2][3] Every listed weekly amount fits within one 1 mL syringe at this concentration.
Reconstitution Steps
- Clean the vial stopper and gather the sterile supplies required by the research procedure.
- Add 3 mL of the documented sterile diluent slowly down the vial wall.
- Gently swirl or roll until dissolved. Do not shake.
- Label the vial 20 mg/mL with the preparation date and follow the exact product storage and discard instructions.
Supplies Needed
Clear 12-week and 24-week planning for a 60 mg vial at 20 mg/mL.
- Tirzepatide vials (60 mg each):
- 12-week schedule: 1 vial needed. Total scheduled amount: 60 mg.
- 24-week schedule: 4 vials needed. Total scheduled amount: 210 mg.
- U-100 insulin syringes (1 mL capacity):
- 12-week schedule: 12 new syringes needed.
- 24-week schedule: 24 new syringes needed.
- Documented sterile diluent (10 mL bottles):
- 12-week schedule: 1 bottle needed. Total diluent volume: 3 mL.
- 24-week schedule: 2 bottles needed. Total diluent volume: 12 mL.
- Alcohol swabs:
- 12-week schedule: 24 swabs minimum. 1 box of 100 covers this minimum.
- 24-week schedule: 48 swabs minimum. 1 box of 100 covers this minimum.
- Sharps container: One appropriately sized container for used syringes.
Stability planning: Vial, syringe, swab, and diluent totals are minimum arithmetic quantities. Follow the exact product documentation for sterility, storage, handling loss, and discard timing.
Protocol Overview
Quick reference for the shared Tirzepatide escalation schedule.
Dosing Protocol
The table converts one shared schedule for this vial concentration.
- Starting step: 2.5 mg once weekly for four weeks.[1][6]
- Next step: 5 mg once weekly beginning at week 5.[1][6]
- Additional steps: 7.5 mg, 10 mg, 12.5 mg, and 15 mg after at least four weeks at each amount when escalation is selected.[1][6]
- Measurement: Use the units and mL displayed beside each weekly amount.
- Consistency: Vial size does not change the weekly schedule.
Storage Instructions
Use the storage directions for the exact supplied formulation.
- Before preparation: Keep the vial dry, protected from light, and stored according to its documentation.
- After preparation: Refrigerate only as permitted by the exact formulation and diluent instructions.
- Labeling: Record the concentration, preparation date, storage conditions, and documented discard date.
- Handling: Avoid unnecessary agitation and follow the exact product instructions.
Important Notes
Practical details for reading the schedule and vial calculations consistently.
- The weekly amounts are identical across every Tirzepatide vial-size page. Only concentration, volume, U-100 units, and supply totals change.
- The 2.5 mg amount is the four-week starting step. The cited maintenance targets are 5 mg, 10 mg, and 15 mg.[1][2][3]
- Each increase is separated by at least four weeks in the current labeled escalation schedule.[1][6]
- Use a new sterile syringe for each injection and place used sharps in an appropriate container.[9][10]
- Record the weekly amount, calculated units, volume, date, and administration site consistently.
How This Works
Tirzepatide activates GIP and GLP-1 receptors. This dual incretin activity was studied using once-weekly subcutaneous schedules in controlled human trials.[1][2][4]
- GIP and GLP-1 receptor activity contributes to glucose-dependent insulin signaling and appetite regulation.
- The extended pharmacokinetic profile supports once-weekly administration in the cited clinical programs.[1][2][4]
- The published trials evaluated manufactured study products with structured escalation and monitoring plans.[2][3][4]
Clinical Benefits
Results below summarize observations from controlled human research.
- SURMOUNT-1 reported dose-related body-weight reductions with 5 mg, 10 mg, and 15 mg weekly target groups through 72 weeks.[2][3]
- SURPASS-1 reported improvements in glycated hemoglobin and body weight across the studied weekly target groups.[4]
- The three-year SURMOUNT-1 analysis reported sustained weight outcomes and evaluated progression to type 2 diabetes in participants with prediabetes.[5]
- Cardiometabolic measurements were evaluated as prespecified or secondary outcomes in the clinical research programs.[2][4][5][7]
Side Effects
Safety findings remain specific to the studied populations, products, schedules, and monitoring plans.
- Gastrointestinal events, including nausea, diarrhea, vomiting, and constipation, were among the most commonly reported events.[1][2][4][6]
- Events occurred most often during dose escalation and were generally mild to moderate in SURMOUNT-1.[2]
- The current prescribing information includes contraindications, warnings, precautions, and interaction information that should be read in full.[1][6]
- Trial results should be compared within the same population, target group, follow-up period, and analysis plan.
Lifestyle Factors
Consistent study conditions make weekly observations easier to interpret.
- Record diet, physical activity, sleep, hydration, and gastrointestinal observations consistently.
- Use the same body-weight, waist, glucose, and laboratory measurement methods throughout the observation period.
- Compare results within the same population, target amount, follow-up period, and analysis plan.
Injection Technique
General subcutaneous research technique should follow the approved institutional or laboratory procedure.[9][10]
- Use a new sterile syringe and needle for every injection and each separate vial entry.
- Clean the vial stopper and selected site, then allow the surface to dry.
- Use the needle length, angle, and skinfold method specified by the governing procedure.
- Rotate sites systematically and document each administration.
- Place used sharps immediately in an appropriate sharps container.
Important Research Note
This page pairs the published Tirzepatide weekly schedule with transparent arithmetic for a nominal 60 mg lyophilized vial. The cited trials and current product label used manufactured dosage forms under structured monitoring.
References
- DailyMed (2026): Zepbound tirzepatide injection: current prescribing information and weekly escalation schedule
- New England Journal of Medicine (2022): Tirzepatide once weekly for the treatment of obesity: SURMOUNT-1 randomized phase 3 trial
- ClinicalTrials.gov: SURMOUNT-1 study record NCT04184622
- The Lancet (2021): SURPASS-1 randomized phase 3 tirzepatide monotherapy trial
- New England Journal of Medicine (2024): Tirzepatide for obesity treatment and diabetes prevention: three-year SURMOUNT-1 findings
- FDA: Zepbound tirzepatide injection prescribing information
- Nature Medicine (2022): Tirzepatide cardiovascular risk factors and safety in type 2 diabetes: SURPASS program analysis
- The Lancet Diabetes and Endocrinology (2023): Tirzepatide for chronic weight management: SURMOUNT clinical development program design
- CDC: Preventing unsafe injection practices and handling multidose vials
- NCBI Bookshelf: Best practices for injections and related procedures